The FDA has expanded the administration options for Hizentra (human normal immunoglobulin 20% liquid), from CSL Behring, to include the...
CSL Limited announced that the FDA has accepted for review CSL Behring’s Biologics License Application (BLA) for its novel investigational...
The FDA has given approval for an expanded indication of Kcentra (prothrombin complex concentrate), from CSL Behring, for use in...
The FDA has approved an extended indication to allow self administration of Berinert (C1 inhibitor concentrate), from CSL Behring, in...
CSL Behring announced that a clinical study examining faster infusion rates and higher volumes than currently approved for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) (SCIg) in patients with primary immunodeficiency (PI) met its primary endpoint
The FDA has approved an expansion of the indication for Corifact (factor XIII Concentrate), from CSL Behring, to include the...
CSL Behring has announced it has enrolled the first patient in COMPACT, an international Phase III study of a volume-reduced,...
Pharmacokinetic results for the recombinant coagulation single-chain factor VIII rVIII-SingleChain, from CSL Behring, showed improved half-life over octocog alfa (the...
New data from a Phase IIIb study shows Kcentra (Prothrombin Complex Concentrate), from CSL Behring, was superior to plasma, the...
The EU has approved an extended use of Berinert (C1 inhibitor concentrate), from CSL Behring, for pre-procedure prevention (short-term prophylaxis)...